Key management considerations include: Continuing prescribed arthritis medications (disease-modifying agents, corticosteroids) as directed Monitoring for new or worsening joint symptoms that may require evaluation Maintaining adequate protein intake (generally 0.8-1.0 g/kg body weight, individualized based on age and kidney function) to preserve muscle mass during weight loss Ensuring sufficient calcium and vitamin D for bone health Reporting severe joint pain, swelling, or functional limitation promptly Patients should seek medical evaluation if they experience sudden onset of severe joint pain, joint swelling with redness or warmth, inability to bear weight, joint symptoms accompanied by fever, or persistent pain lasting more than 6 weeks
These effects are usually mild and improve over time
Contact your GP if you experience amenorrhoea for three months, very heavy bleeding, intermenstrual bleeding, severe pain, or any possibility of pregnancy
A licensed healthcare provider will review your health and medical history to determine if you qualify for GLP-1 treatment and discuss your options with you before prescribing medication
When deciding which of these GLP-1 receptor agonist medications is best for a patient, we discuss other factors like whether theyll struggle with daily injections (favoring semaglutide) or are prone to gastrointestinal symptoms (favoring liraglutide), Watson says
16 In October 2024, Novo Nordisk entered a settlement with Natco Pharma and Mylan (a subsidiary of Viatris) in relation to its product Ozempic
.png.jpg)
